| [1] |
Freddie B, Jacques F, Isabelle S , et al. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA: A Cancer Journal for Clinicians, 2018.
doi: 10.1002/ijc.31937
pmid: 30350310
|
| [2] |
Jemal A, Ward EM, Johnson CJ , et al. Annual report to the nation on the status of cancer, 1975-2014, featuring survival. J Natl Cancer Inst 2017; 109(9).
|
| [3] |
London WT, Petrick JL, McGlynn KA . Liver cancer. In: Thun MJ, Linet MS, Cerhan JR, Haiman CA, Schottenfeld D, eds. Cancer Epidemiology and Prevention. 4th ed. New York: Oxford University Press; 2018: 635-660.
|
| [4] |
Ishizawa T, Hasegawa K, Aoki T , et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 2008; 134:1908-16.
doi: 10.1053/j.gastro.2008.02.091
pmid: 18549877
|
| [5] |
Bruix J, Takayama T, Mazzaferro V , et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 2015; 16:1344-54.
|
| [6] |
Zhang W, Wang X, Jiang R , et al. Effect of Tumor Size on Cancer-Specific Survival in Small Hepatocellular Carcinoma[J]. Mayo Clinic Proceedings, 2015: S002561961500542X.
doi: 10.1016/j.mayocp.2019.10.008
pmid: 31785831
|
| [7] |
Lee W C, Jeng L B, Chen M F . Estimation of prognosis after hepatectomy for hepatocellular carcinoma[J]. British Journal of Surgery, 2002,89(3):311-6.
doi: 10.1046/j.0007-1323.2001.02034.x
pmid: 11872055
|
| [8] |
Prognostic Significance of Vascular Endothelial Growth Factor, Basic Fibroblast Growth Factor, and Angiogenin in Patients With Resectable Hepatocellular Carcinoma After Surgery[J]. Annals of Surgical Oncology, 2003,10(4):355-362.
doi: 10.1245/ASO.2003.10.002
|
| [9] |
Cucchetti A, Piscaglia F, Cescon M , et al. Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. J Hepatol 2013; 59:300-7.
|
| [10] |
B. Schlütter . Adherence to American Association for the Study of Liver Diseases guidelines for the management of hepatocellular carcinoma: results of an Italian field practice multicenter study.[J]. Future Oncology, 2013,9(2):283-294.
doi: 10.2217/FON.12.183
|
| [11] |
Yamasaki S, Hasegawa H, Kinoshita H , et al. A Prospective Randomized Trial of the Preventive Effect of Pre-operative Transcatheter Arterial Embolization against Recurrence of Hepatocellular Carcinoma[J]. Jpn J Cancer Res, 1996,87(2):206-211.
doi: 10.1111/j.1349-7006.1996.tb03160.x
pmid: 8609071
|
| [12] |
François Paye, Jagot P, Valérie Vilgrain , et al. Preoperative Chemoembolization of Hepatocellular Carcinoma: A Comparative Study[J]. Archives of Surgery, 1998,133(7):767.
doi: 10.1001/archsurg.133.7.767
pmid: 9688007
|
| [13] |
刘鹏飞, 刘荣华, 徐荷 , et al. 原发性肝癌术后预防性TACE的意义(附433例病例随访)[J]. 中华肝胆外科杂志, 2005.
|
| [14] |
Maeda S, Fujiyama S, Tanaka M , et al. Survival and local recurrence rates of hepatocellular carcinoma patients treated by transarterial chemolipiodolization with and without embolization[J]. Hepatology Research, 2002,23(3):202-210.
doi: 10.1016/s1386-6346(01)00174-7
pmid: 12076716
|
| [15] |
Mathurin P, Raynard B, Dharancy S , et al. Meta-analysis: Evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma[J]. Alimentary Pharmacology & Therapeutics, 2003,17(10):1247-1261.
doi: 10.1111/bcp.14176
pmid: 31747468
|
| [16] |
Ono T, Yamanoi A, Osama N E A , et al. Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long‐term prognosis in cirrhotic patients[J]. Cancer, 2015,91(12):2378-2385.
pmid: 11413528
|
